Skip to main content
Defiance International

Published study records

Study records for Thymosin Alpha 1

Study records describe published research and its limitations. They do not establish efficacy, safety, or suitability for any use.

Study record counts

399 study records.

12 evidence-verified · 265 citation-verified · 121 identifier-confirmed · 1 citation-only

Listed by tier, then records with a public summary first, then publication year, newest first, undated last.

Verified records by research setting

  • In vitro: 88
  • In vivo/preclinical: 90
  • Review/meta-analysis: 38
  • Other: 0
Filter study recordsReset filters

Filtered results

Study type: Human research · Verification: Citation verified

  • 2006

Hepatitis B virus genotype B is associated with better response to thymosin alpha1 therapy than genotype C.

Journal of viral hepatitis · 2006

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Citation verified

  • 2005

Thymosin alpha 1 attenuates lipid peroxidation and improves fructose-induced steatohepatitis in rats.

Clinical biochemistry · 2005

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: Human research · Verification: Citation verified

  • 2005

The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial.

Journal of viral hepatitis · 2005

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Citation verified

  • 2005

Immunomodulatory function of orally administered thymosin alpha1.

Journal of Zhejiang University. Science. B · 2005

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vitro · Verification: Citation verified

  • 2005

Activation of IKK by thymosin alpha1 requires the TRAF6 signalling pathway.

EMBO reports · 2005

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Citation verified

  • 2005

Construction and application of a yeast expression system for thymosin alpha1.

Biocell : official journal of the Sociedades Latinoamericanas de Microscopia Electronica ... et. al · 2005

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: Narrative review · Verification: Citation verified

  • Literature
  • 2005

Thymalfasin for the treatment of chronic hepatitis C infection.

Expert review of anti-infective therapy · 2005

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-09-14, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Citation verified

  • 2005

[Combination of lamivudine with thymosin alpha1 in treatment of duck hepatitis B].

Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2005

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: Human research · Verification: Citation verified

  • 2004

Thymosin alpha 1 in combination with interferon alpha and ribavirin in chronic hepatitis C patients who are non-responders or relapsers to interferon alpha plus ribavirin.

JPMA. The Journal of the Pakistan Medical Association · 2004

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: Human research · Verification: Citation verified

  • 2004

Combination transcatheter hepatic arterial chemoembolization with thymosin alpha1 on recurrence prevention of hepatocellular carcinoma.

Hepato-gastroenterology · 2004

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Citation verified

  • 2004

Activation of tumor-associated macrophages by thymosin alpha 1.

International journal of immunopathology and pharmacology · 2004

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: Narrative review · Verification: Citation verified

  • 2004

Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B.

Journal of gastroenterology and hepatology · 2004

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation verified. The PMID shown was confirmed at PubMed on 2026-08-16, and its study type matched the catalog’s source record. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.